Antifibrotic combo therapy reduces biomarkers in IPF
AusDoc brings you the latest news from the European Respiratory Society Congress 2020.
A post-hoc analysis of results from the INSTAGE trial shows that treatment with a combination of nintedanib and sildenafil affects three biomarkers relating to idiopathic pulmonary fibrosis (IPF).
In the INSTAGE trial of people with IPF and a predicted lung diffusion capacity for carbon monoxide (DLCO) of 35% or below, no benefit was found from the combination therapy vs nintedanib alone as measured by improvements in scores on the St George’s Respiratory Questionnaire at week 12.
The subgroup analysis investigating 13 biomarkers in 268 patients (mean age 70 years) whose emphysema status was known (36% with emphysema) was presented at the European Respiratory Society international virtual congress (ERS 2020) last week.
